Nls Pharmaceutics Ag Stock Analysis
| NLSPW Stock | USD 0.01 0 18.18% |
NLS Pharmaceutics AG is overvalued with Real Value of 0.00864 and Hype Value of 0.0106. The main objective of NLS Pharmaceutics stock analysis is to determine its intrinsic value, which is an estimate of what NLS Pharmaceutics AG is worth, separate from its market price. There are two main types of NLS Pharmaceutics' stock analysis: fundamental analysis and technical analysis.
The NLS Pharmaceutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NLS Pharmaceutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. NLS Stock trading window is adjusted to America/New York timezone.
NLS |
NLS Stock Analysis Notes
The company had not issued any dividends in recent years. NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Nls Pharmaceutics is traded on NASDAQ Exchange in the United States. To find out more about NLS Pharmaceutics AG contact Alexander Zwyer at 41 44 512 21 50 or learn more at https://nlspharma.com.NLS Pharmaceutics Investment Alerts
| NLS Pharmaceutics is way too risky over 90 days horizon | |
| NLS Pharmaceutics has some characteristics of a very speculative penny stock | |
| NLS Pharmaceutics appears to be risky and price may revert if volatility continues | |
| NLS Pharmaceutics has high likelihood to experience some financial distress in the next 2 years | |
| NLS Pharmaceutics AG has accumulated 1.63 M in total debt. NLS Pharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NLS Pharmaceutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from accesswire.com: NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders |
NLS Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.77 M.NLS Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.59) | (6.92) | |
| Return On Capital Employed | 1.94 | 2.04 | |
| Return On Assets | (6.59) | (6.92) | |
| Return On Equity | 1.38 | 1.45 |
Management Efficiency
NLS Pharmaceutics has return on total asset (ROA) of (2.2776) % which means that it has lost $2.2776 on every $100 spent on assets. This is way below average. NLS Pharmaceutics' management efficiency ratios could be used to measure how well NLS Pharmaceutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NLS Pharmaceutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.45 in 2024, whereas Return On Tangible Assets are likely to drop (6.92) in 2024. At this time, NLS Pharmaceutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 971.7 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 16 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.23) | (0.24) | |
| Tangible Book Value Per Share | (0.23) | (0.24) | |
| Enterprise Value Over EBITDA | (76.18) | (79.99) | |
| Price Book Value Ratio | (101.65) | (96.56) | |
| Enterprise Value Multiple | (76.18) | (79.99) | |
| Price Fair Value | (101.65) | (96.56) | |
| Enterprise Value | 898.6 M | 1.1 B |
Effective leadership at NLS Pharmaceutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta (0.52) | Return On Assets (2.28) |
Technical Drivers
As of the 27th of November, NLS Pharmaceutics secures the Market Risk Adjusted Performance of (0.78), mean deviation of 22.79, and Risk Adjusted Performance of 0.0961. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of NLS Pharmaceutics, as well as the relationship between them. Please verify NLS Pharmaceutics information ratio and downside variance to decide if NLS Pharmaceutics AG is priced more or less accurately, providing market reflects its recent price of 0.009 per share. As NLS Pharmaceutics appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.NLS Pharmaceutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NLS Pharmaceutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NLS Pharmaceutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NLS Pharmaceutics Predictive Daily Indicators
NLS Pharmaceutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NLS Pharmaceutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.82 | |||
| Day Median Price | 0.009 | |||
| Day Typical Price | 0.009 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0) |
NLS Pharmaceutics Forecast Models
NLS Pharmaceutics' time-series forecasting models are one of many NLS Pharmaceutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NLS Pharmaceutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NLS Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NLS Pharmaceutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NLS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NLS Pharmaceutics. By using and applying NLS Stock analysis, traders can create a robust methodology for identifying NLS entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding NLS Pharmaceutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.